How peptides are regulated
A plain-language guide to how peptides are regulated: the four lanes, the compounding gates, and the three things people most often get wrong.
The four lanes
Any peptide sits in one of four lanes — and people constantly mix them up. A peptide can be an approved drug that cleared full FDA review and is legal to prescribe and sell as medicine (rare for peptides).S1 It can be compounded — prepared by a licensed pharmacy without full approval, legal only under specific conditions, which is not the same as being FDA-approved.S1 It can be a dietary supplement, a separate legal track for ingredients that qualify under the supplement law.S4 Or it can be a gray-market "research chemical", sold "for research use only, not for human consumption" — not legal to sell for human use, with no FDA oversight of what's in the vial.S1
Anti-doping status is a separate overlay: a substance can be a legal supplement and still banned in sport, or vice versa.S2
The compounding gates
To be compounded from a bulk substance, a peptide has to clear one gate: it has an official quality monograph, it's a component of an approved drug, or it's on the 503A Bulks List.S1 Getting onto that list is a multi-step process, and each step gets mistaken for the finish line: a substance is nominated, then sorted into Category 1 (no significant safety flag during review) or Category 2 (may present safety risks — don't compound meanwhile), or its nomination is withdrawn.S2 An advisory committee (PCAC) then recommends yes or no, FDA decides, and if yes does rulemaking to actually add it to the list.S3
Three common mix-ups
"Removed from Category 2 means it's legal." No — removal is a procedural step; it does not put a substance on the 503A list and does not make it eligible to compound.S2 "The advisory committee decides." No — PCAC only recommends; FDA makes the decision and then has to do rulemaking.S3 "Compounded means FDA-approved." No — compounding is an exception to approval, not a form of it.S1
Where the peptides sit
Every compound on this site is mapped to its lane and stage on the status map — from FDA-approved drugs, to peptides under active PCAC review, to the many that sit in the gray market. The key takeaway carries across all of them: being for sale is not the same as being proven, legal, or safe.
Sources
Every reference below is a primary source cited in this entry, drawn from the approved corpus.
-
01
FDA — Human Drug Compounding (503A / 503B overview)fda.gov · Federal regulatory overview
-
02
FDA — Certain Bulk Drug Substances for Use in Compounding (Category 2)fda.gov · Federal regulatory listing
-
03
Federal Register — PCAC Notice of Meeting; 503A Bulk Drug Substances List (91 FR 20465)federalregister.gov · Federal Register notice
-
04
FDA — Dietary Supplementsfda.gov · Federal regulatory overview
Follow this compound
Get an email when FDA / WADA / ClinicalTrials moves on How peptides are regulated.
Follow thisThe Panel Brief
What moved in supplement & peptide regulation this week. Free, cited, unsubscribe anytime.